NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...
Since the publication of this paper, the authors have noticed that there are several instances in which micrograms were published as milligrams in the Methods section. The correct Methods section is ...
In most cases, the targeted microbubble contrast agents (MCAs) are fitted with a high-affinity targeting ligand. After the MCAs are adhered to the target, they begin to improve the acoustic signal ...
London: The ultrasound contrast agents (microbubbles) market is driven by their role in enhancing diagnostic capabilities and revolutionising treatment methods. The demand for microbubbles will stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results